Compare NHI & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHI | RNA |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | United States | United States |
| Employees | N/A | 391 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 227.6M |
| IPO Year | 1994 | 2025 |
| Metric | NHI | RNA |
|---|---|---|
| Price | $85.22 | $14.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $85.20 | $69.26 |
| AVG Volume (30 Days) | 284.3K | ★ 2.6M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.02 | N/A |
| Revenue | ★ $375,628,000.00 | N/A |
| Revenue This Year | $11.74 | $88.12 |
| Revenue Next Year | $9.02 | $18.11 |
| P/E Ratio | $28.45 | ★ N/A |
| Revenue Growth | ★ 12.07 | N/A |
| 52 Week Low | $66.41 | $13.06 |
| 52 Week High | $91.38 | $73.06 |
| Indicator | NHI | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 5.54 |
| Support Level | $77.64 | $13.06 |
| Resistance Level | $91.38 | $72.52 |
| Average True Range (ATR) | 2.06 | 0.93 |
| MACD | -0.58 | -3.73 |
| Stochastic Oscillator | 27.24 | 2.73 |
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.